CareDx built a name for themselves with a diagnostics platform that helped improve outcomes for transplant patients. The company has since branched out into several other areas of medicine, where they’re using genomics to help clinicians make more informed patient care decisions.
Our guest today is John Hanna, CEO of CareDx, a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy.
John brings over two decades of executive leadership at the intersection of technology development and revenue growth in the molecular diagnostics and life sciences tools industry. His experience includes a stint as CEO of Apton Biosystems, where he led the development of a high throughput next generation sequencing platform for liquid biopsy and other clinical applications, and 10 years at Veracyte, an oncology diagnostics company, where he held several roles including Chief Commercial Officer and VP of marketing.
John joins us today to discuss his unique journey from health insurance lobbyist to CEO of a diagnostics company, how the CareDx platform is helping improve patient outcomes across different areas of medicine, and how integrating AI will improve their product offerings.
Highlights:
- From Health Insurance Lobbyist to Diagnostics (2:45)
- Transforming CareDx Beyond Transplant (5:55)
- Why Viral Cancers Are the Focus (10:55)
- Buying a Proven Product and Growing the Team (13:55)
- Catching Organ Rejection Early (16:20)
- Building Tests Doctors Actually Need (19:50)
- A Gentler Way to Catch Cancer Relapse (21:55)
- Earning Doctors’ Trust in New Tests (26:15)
- How AI Is Changing the Business (29:35)
- Priorities for 2027 (33:10)
Links:
Feedback:
If you have questions about the show, or have a topic in mind you’d like discussed in future episodes, email our producer, [email protected].
Publisher: Source link
